NASDAQ:RETA

Reata Pharmaceuticals News Headlines

$84.76
-0.30 (-0.35 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$82.00
$85.49
50-Day Range
$85.06
$115.66
52-Week Range
$82.00
$186.82
Volume368,359 shs
Average Volume305,514 shs
Market Capitalization$3.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57

Headlines

Reata Pharmaceuticals (NASDAQ RETA) News Headlines Today

SourceHeadline
Reata Pharmaceuticals (NASDAQ:RETA) Sets New 1-Year Low at $83.51Reata Pharmaceuticals (NASDAQ:RETA) Sets New 1-Year Low at $83.51
americanbankingnews.com - May 10 at 2:43 PM
Reata Pharmaceuticals (NASDAQ:RETA) Issues  Earnings ResultsReata Pharmaceuticals (NASDAQ:RETA) Issues Earnings Results
americanbankingnews.com - May 9 at 3:20 PM
 Brokerages Anticipate Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to Announce -$2.40 Earnings Per Share Brokerages Anticipate Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to Announce -$2.40 Earnings Per Share
americanbankingnews.com - May 8 at 1:22 PM
Reata Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call PresentationReata Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 7 at 7:57 PM
Reata Pharmaceuticals (NASDAQ:RETA) Trading Down 4.8%Reata Pharmaceuticals (NASDAQ:RETA) Trading Down 4.8%
americanbankingnews.com - May 7 at 1:42 PM
Reata Pharmaceuticals (NASDAQ:RETA) Now Covered by Analysts at BarclaysReata Pharmaceuticals (NASDAQ:RETA) Now Covered by Analysts at Barclays
americanbankingnews.com - May 3 at 10:19 AM
Reata Pharmaceuticals Announces Presentations at Upcoming Investor ConferencesReata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences
finance.yahoo.com - May 3 at 9:29 AM
Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q1 Earnings Expected to DeclineEarnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q1 Earnings Expected to Decline
finance.yahoo.com - April 29 at 8:20 PM
Reata Pharmaceuticals (RETA) Scheduled to Post Earnings on ThursdayReata Pharmaceuticals (RETA) Scheduled to Post Earnings on Thursday
americanbankingnews.com - April 29 at 8:36 AM
WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant GliomasWPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas
feeds.benzinga.com - April 27 at 7:40 AM
Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport SyndromeReata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
finance.yahoo.com - April 26 at 6:41 PM
Reata Pharmaceuticals (NASDAQ:RETA) Trading Up 9.4%Reata Pharmaceuticals (NASDAQ:RETA) Trading Up 9.4%
americanbankingnews.com - April 26 at 1:46 PM
Is RETA Stock A Buy or Sell?Is RETA Stock A Buy or Sell?
finance.yahoo.com - April 26 at 1:40 PM
Financial Contrast: Reata Pharmaceuticals (NASDAQ:RETA) versus Immuron (NASDAQ:IMRN)Financial Contrast: Reata Pharmaceuticals (NASDAQ:RETA) versus Immuron (NASDAQ:IMRN)
americanbankingnews.com - April 22 at 4:24 AM
Reata Pharmaceuticals Announces Presentations at Upcoming Medical ConferencesReata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences
finance.yahoo.com - March 29 at 8:58 PM
Reata Pharmaceuticals Stock Shows Every Sign Of Being Significantly OvervaluedReata Pharmaceuticals Stock Shows Every Sign Of Being Significantly Overvalued
finance.yahoo.com - March 29 at 3:13 PM
Reata Pharmaceuticals, Inc. Submits NDA for Companys Lead Program: Bardoxolone in Alport SyndromeReata Pharmaceuticals, Inc. Submits NDA for Company's Lead Program: Bardoxolone in Alport Syndrome
benzinga.com - March 3 at 8:03 AM
Reata Pharma Shares Are Trading Higher After Filing US Application In Alport Syndrome-Related Kidney DiseaseReata Pharma Shares Are Trading Higher After Filing US Application In Alport Syndrome-Related Kidney Disease
finance.yahoo.com - March 1 at 6:05 PM
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport SyndromeReata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome
finance.yahoo.com - March 1 at 7:28 AM
Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport SyndromeReata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome
finance.yahoo.com - March 1 at 7:28 AM
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development ProgramsReata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and Provides an Update on Clinical Development Programs
finance.yahoo.com - March 1 at 7:28 AM
Reata Pharmaceuticals, Inc. (RETA) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseReata Pharmaceuticals, Inc. (RETA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
finance.yahoo.com - February 10 at 5:05 PM
Best Biotech Stocks to Buy in 2021Best Biotech Stocks to Buy in 2021
msn.com - February 2 at 12:01 AM
RETA Aug 2021 95.000 putRETA Aug 2021 95.000 put
uk.finance.yahoo.com - January 28 at 12:02 AM
RETA Aug 2021 65.000 putRETA Aug 2021 65.000 put
uk.finance.yahoo.com - January 28 at 12:02 AM
Relative Strength Alert For Reata PharmaceuticalsRelative Strength Alert For Reata Pharmaceuticals
nasdaq.com - January 6 at 1:40 PM
RETA Jan 2021 170.000 callRETA Jan 2021 170.000 call
uk.finance.yahoo.com - January 2 at 10:21 PM
RETA Jan 2021 110.000 callRETA Jan 2021 110.000 call
uk.finance.yahoo.com - December 21 at 8:42 PM
An Intrinsic Calculation For Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Suggests Its 50% UndervaluedAn Intrinsic Calculation For Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Suggests It's 50% Undervalued
finance.yahoo.com - December 21 at 3:42 PM
RETA Jan 2021 145.000 putRETA Jan 2021 145.000 put
uk.finance.yahoo.com - December 20 at 10:37 PM
RETA Final Deadline Notice: Rosen, Top Ranked Investor Counsel, Reminds Reata Pharmaceuticals, Inc. Investors of Important Deadline Today in Securities Class Action - RETARETA Final Deadline Notice: Rosen, Top Ranked Investor Counsel, Reminds Reata Pharmaceuticals, Inc. Investors of Important Deadline Today in Securities Class Action - RETA
finance.yahoo.com - December 14 at 12:23 PM
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmDEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - December 14 at 12:23 PM
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - December 14 at 12:23 PM
FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmFINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - December 14 at 1:20 AM
RETA FINAL DEADLINE ALERT: ROSEN, TRUSTED AND LEADING INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action - RETARETA FINAL DEADLINE ALERT: ROSEN, TRUSTED AND LEADING INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action - RETA
markets.businessinsider.com - December 12 at 6:24 PM
DECEMBER 14 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmDECEMBER 14 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - December 12 at 2:28 PM
LEADING AND LONGSTANDING Rosen Law Firm Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action - RETALEADING AND LONGSTANDING Rosen Law Firm Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action - RETA
finance.yahoo.com - December 11 at 11:43 PM
IMMINENT DEADLINE Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. – RETAIMMINENT DEADLINE Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. – RETA
finance.yahoo.com - December 11 at 1:31 PM
IMMINENT DEADLINE Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. – RETAIMMINENT DEADLINE Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. – RETA
benzinga.com - December 11 at 12:41 PM
RETA FINAL DEADLINE: Top Ranked Rosen Law Firm Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action - RETARETA FINAL DEADLINE: Top Ranked Rosen Law Firm Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action - RETA
finance.yahoo.com - December 10 at 5:20 PM
MONDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmMONDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - December 10 at 12:20 PM
DEADLINE MONDAY ALERT: The Schall Law Firm Announces it is Investigating Claims Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmDEADLINE MONDAY ALERT: The Schall Law Firm Announces it is Investigating Claims Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
finance.yahoo.com - December 9 at 8:27 PM
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmDEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
finance.yahoo.com - December 8 at 10:30 PM
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmMONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - December 8 at 5:25 PM
DEC. 14 DEADINE:  Pawar Law Group Announces a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.– RETADEC. 14 DEADINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.– RETA
finance.yahoo.com - December 8 at 5:25 PM
Rosen, A Top Ranked Law Firm, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - RETARosen, A Top Ranked Law Firm, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - RETA
finance.yahoo.com - December 7 at 9:14 PM
FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmFINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - December 7 at 4:13 PM
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action – RETAROSEN, GLOBAL INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action – RETA
feeds.benzinga.com - December 4 at 6:19 PM
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock OfferingReata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Offering
finance.yahoo.com - December 4 at 1:49 PM
Stock Alert: Reata Pharmaceuticals Falls 10%Stock Alert: Reata Pharmaceuticals Falls 10%
nasdaq.com - December 2 at 3:52 PM
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.